12:00 AM
 | 
Nov 17, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Adlea capsaicin: Phase III data

The double-blind, U.S. Phase III ACTIVE-1 trial in 301 patients showed that Adlea missed the primary endpoint of reducing post-surgical pain as measured by a time-weighted pain score at 4 to 32 hours...

Read the full 142 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >